A Direct Comparison of Anti-microRNA Oligonucleotide Potency

被引:132
作者
Lennox, Kim A. [1 ]
Behlke, Mark A. [1 ]
机构
[1] Integrated DNA Technol, Coralville, IA 52241 USA
关键词
antagonist; antisense; LNA; miRNA; potency; XENOPUS-LAEVIS EMBRYOS; LOCKED NUCLEIC-ACIDS; ANTISENSE OLIGONUCLEOTIDES; IN-VIVO; LIPID-METABOLISM; MESSENGER-RNAS; HUMAN-DISEASE; LNA; MIRNAS; DEGRADATION;
D O I
10.1007/s11095-010-0156-0
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose Cataloguing endogenous miRNA targets by inhibiting miRNA function is fundamental to understanding the biological importance of each miRNA in gene regulatory pathways. Methods to down-regulate miRNA activity may help treat diseases where over-expression of miRNAs relates to the underlying pathophysiology. This study objectively evaluates the in vitro potency of different anti-miRNA oligonucleotides (AMOs) using various design and modification strategies described in the literature as well as some novel modification strategies. Methods MiR21 and miR16 AMOs, containing chemical modifications such as 2'-O-methyl RNA, locked nucleic acid and 2'-Fluoro bases with or without phosphorothioate linkages, were directly compared by transfection into HeLa cells using a dual-luciferase reporter assay to quantify miRNA inhibition. Results Potency for the various AMOs ranged from inactive at high dose (50 nM) to strongly inhibitory at both high and low dose (1 nM). Including phosphorothioate linkages improved nuclease stability and generally increased functional potency. Conclusions Incorporating high binding affinity modifications, such as LNA and 2'F bases, increases AMO potency while maintaining specificity; nevertheless, use of low dose is preferred when using high potency reagents to minimize the potential for cross reactivity. 2'OMe/LNA chimeras with PS modifications were the most potent constructs tested for miRNA inhibition in vitro.
引用
收藏
页码:1788 / 1799
页数:12
相关论文
共 54 条
[1]   MicroRNA functions in animal development and human disease [J].
Alvarez-Garcia, I ;
Miska, EA .
DEVELOPMENT, 2005, 132 (21) :4653-4662
[2]   MicroRNAs: Target Recognition and Regulatory Functions [J].
Bartel, David P. .
CELL, 2009, 136 (02) :215-233
[3]  
BROWN DA, 1994, J BIOL CHEM, V269, P26801
[4]   microRNAs in neurodegeneration [J].
Bushati, Natascha ;
Cohen, Stephen M. .
CURRENT OPINION IN NEUROBIOLOGY, 2008, 18 (03) :292-296
[5]   Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs [J].
Cai, XZ ;
Hagedorn, CH ;
Cullen, BR .
RNA, 2004, 10 (12) :1957-1966
[6]   Origins and Mechanisms of miRNAs and siRNAs [J].
Carthew, Richard W. ;
Sontheimer, Erik J. .
CELL, 2009, 136 (04) :642-655
[7]   MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells [J].
Chan, JA ;
Krichevsky, AM ;
Kosik, KS .
CANCER RESEARCH, 2005, 65 (14) :6029-6033
[8]   Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis [J].
Cheng, AM ;
Byrom, MW ;
Shelton, J ;
Ford, LP .
NUCLEIC ACIDS RESEARCH, 2005, 33 (04) :1290-1297
[9]   Design and characterization of decoy oligonucleotides containing locked nucleic acids [J].
Crinelli, R ;
Bianchi, M ;
Gentilini, L ;
Magnani, M .
NUCLEIC ACIDS RESEARCH, 2002, 30 (11) :2435-2443
[10]   Causes and consequences of microRNA dysregulation in cancer [J].
Croce, Carlo M. .
NATURE REVIEWS GENETICS, 2009, 10 (10) :704-714